Recombinant Human FCRL2/IRTA4 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00968P-100UG

Human FCRL2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human FCRL2/IRTA4 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00968P-100UG
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human FCRL2/IRTA4 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Leu20-Val401. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | Q96LA5 |
Target Symbol | FCRL2/IRTA4 |
Synonyms | FcR-like protein 2; FcRL2; FCRH2; IFGP4; IRTA4; FCRL2; CD307b; FCRH2SPAP1B; IRTA4SPAP1C; SPAP1; SPAP1A |
Species | Human |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Leu20-Val401 |
Mol. Weight | The protein has a predicted MW of 42.7 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human FCRL2, His Tag at 0.5ug/ml (100ul/well) on the plate. Dose response curve for Anti-FCRL2 Antibody, hFc Tag with the EC50 of 0.13ug/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Fc receptor-like 2 (FCRL2) is highly expressed on B-cell chronic lymphocytic leukemia (B-CLL) cells and could possibly influence disease pathogenesis. FCRL2 mRNA expression was found to be expressed at considerably higher levels in peripheral blood mononuclear cells (PBMC) of B-CLL patients compared to controls (range 1.35- to 210-fold upregulation; P < 0.0001) and cells of other hematological diseases. |